Valneva SE to host investor day today in New York City to discuss the Company’s key value drivers over the next 12-18 months and beyond (5.69)
Valneva's Chief Executive Officer Thomas Lingelbach, Chief Financial Officer Peter Bühler, and other members of the Company's senior leadership team will highlight the Company's substantial opportunity for its Lyme disease vaccine candidate led by partner Pfizer (PFE), Valneva's growing commercial vaccine business, and opportunities for continued value creation from the Company's promising R&D pipeline. Valneva will highlight the following:
- VLA15, its vaccine candidate against Lyme disease, which is currently fully enrolled with primary vaccination series completed in the pivotal Phase 3 study led by Pfizer
- The Company's revenue-generating commercial portfolio of traveler's vaccines, including the ongoing launches of IXCHIQ against chikungunya virus
- The Company's clinical and preclinical R&D pipeline, which includes ongoing clinical development for IXCHIQ (Phase 4 and other studies), SV4 against Shigella in Phase 2, and VLA1601 against
- Zika virus in Phase 1. Valneva will also discuss further R&D pipeline development and selected current lead targets.
- There will also be a brief financial overview highlighting 2024 and mid-term guidance.